Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019

Jennifer Jones's Biography



Jennifer Jones, NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute

Dr. Jones is NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology at the Center for Cancer Research, National Cancer Institute, who is developing, refining, and applying advanced high-resolution flow cytometric methods to the characterization of EV subsets. She initiated/cofounded the international ISEV-ISAC-ISTH EV Flow Cytometry Working Group, to support the development of consensus best practices and standardization methods for the field. The ultimate goal of her research is to develop a new class of EV-based biomarkers (and methods for anlyzing those EVs) that will enable adaptve therapeutic strategies, where individual patient treatments are customized based on early responses to treatment.

Jennifer Jones Image

Mt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical Biofluids

Wednesday, 27 March 2019 at 09:00

Add to Calendar ▼2019-03-27 09:00:002019-03-27 10:00:00Europe/LondonMt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical BiofluidsLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Because Extracellular Vesicles (EVs) carry surface receptors that are characteristic of their cells of origin, EVs have tremendous potential as non-invasive biomarkers for diagnosis, risk-stratification, treatment selection, and treatment monitoring. We developed a first-in-class pipeline to characterize EV heterogeneity and provide high-sensitivity quantification of informative EVs in biofluids before, during, and after treatment. By combining multiplex assays with high-resolution, single EV flow cytometric methods together into a Mutiplex-to-Single EV Analysis (Mt-SEA) pipeline, we are able to characterize a broad range of relevant EV subsets, while also accurately measuring the concentration of specific EV populations.  Detection of tumor-associated EVs and detection of EV repertoire changes during treatment paves the way to future evaluation of EVs as as biomarkers for use in personalized, adaptive therapies.


Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com